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ABSTRACT
Background: Mutation analysis and cytogenetic testing in clear cell renal cell 
carcinoma (ccRCC) is not yet implemented in a routine diagnostics of ccRCC.
Material and methods: We characterized the chromosomal alterations in 83 ccRCC 
tumors from Polish patients using whole genome SNP genotyping assay. Moreover, the 
utility of next generation sequencing of cell free DNA (cfDNA) in patients plasma as 
a potential tool for non-invasive cytogenetic analysis was tested. Additionally, tumor 
specific somatic mutations in PBRM1, BAP1 and KDM5C were determined.
Results: We confirmed a correlation between deletions at 9p and higher tumor 
size, and deletion of chromosome 20 and the survival time. In Fuhrman grade 1, only 
aberrations of 3p and 8p deletion, gain of 5q and 13q and gains of chromosome 7 and 16 
were present. The number of aberrations increased with Fuhrman grade, all chromosomes 
displayed cytogenetic changes in G3 and G4. ccRCC specific chromosome aberrations were 
observed in cfDNA, although discrepancies were found between cfDNA and tumor samples. 
In total 12 common and 94 rare variants were detected in PBRM1, BAP1 and KDM5C, with 
four potentially pathogenic variants. We observed markedly lower mutation load in PBRM1.
Conclusions: Cytogenetic analysis of cfDNA may allow more accurate diagnosis of 
tumor aberrations and therefore the correlation between the chromosome aberrations 
in cfDNA and clinical outcome should be studied in larger cohorts. The functional studies 
on in BAP1, KDM5C, PBRM1 mutations in large, independent sample set would be 
necessary for the assessment of their prognostic and diagnostic potential.
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INTRODUCTION
Kidney cancer represents 2–3% of all adult malign-
ancies diagnosed annually [1]. Renal cell carcinomas (RCC) 
originating from the renal cortex are the most common form 
of all primary renal neoplasms. RCC consists of several 
histological subtypes with distinct molecular alterations and 
clinical outcomes, the most common (70-80% of cases) and 
aggressive being clear cell renal cell carcinoma (ccRCC) [2].
In over 70% of sporadic ccRCC cases, von Hippel–
Lindau (VHL) tumor suppressor gene inactivation through 
sequence alteration, promoter CpG hypermethylation or loss 
of heterozygosity has been reported [3–5]. Germline VHL 
mutations are also linked to an increased risk of developing 
ccRCC in patients with the inherited disorder von Hippel–
Lindau syndrome [6]. VHL protein (pVHL) is involved in 
many cellular processes. Its best characterized function is the 
regulation of response to oxygen level changes by targeting 
hypoxia-inducible factors (HIFs) for ubiquitin-dependent 
proteasomal degradation [6]. pVHL inactivation results in 
constitutive HIFs activity leading to enhanced angiogenesis 
and cell proliferation thus stimulating tumor growth. Recent 
studies showed that in cell lines and mice defective in pVHL 
mitotic spindle checkpoint function is impaired, contributing 
to chromosomal instability that may stimulate tumor 
progression [7, 8].
VHL mutations are not the only driving force in ccRCC 
tumorigenesis. Recent large-scale sequencing studies have 
revealed frequent mutations affecting chromatin modifying 
genes such as PBRM1, BAP1, SETD2, KDM5C and KMD6A 
[9–11]. PBRM1, SETD2 and BAP1, similarly to VHL, map 
to the 3p21 and this suggests that essential component of 
ccRCC pathogenesis may be allelic loss of 3p resulting in 
haploinsufficiency for four tumor suppressors simultaneously. 
Moreover, mutations in BAP1 and SETD2 are probably 
secondary events to VHL or PBRM1 loss [12, 13]. Sequencing 
projects have also identified potentially pathogenic mutations 
of the known tumor suppressor genes CDKN2A, TP53, 
NF2, and PTEN in a subset of ccRCC tumors [9] as well as 
mutations in PI3K pathway regulators mTOR and PIK3CA, 
frequently abolished in many cancers [14].
In addition to gene mutations, chromosomal alterations 
characteristic for ccRCC have been identified in a number 
of high-resolution cytogenetic tumor studies on a genome-
wide level, including array-based comparative genomic 
hybridization (aCGH) and high-density SNP genotyping 
arrays [15–18]. The most frequent genomic changes are 
deletion of chromosome 3p harboring VHL gene (70-80%) 
and/or loss of heterozygosity (LOH) at 3p, as well as gain 
of chromosome 5q (50–60%) [5]. Other chromosomal 
imbalances have also been reported, in a large study 
encompassing 763 patients with ccRCC from Central and 
Eastern European population the most common were deletion 
of chromosome 14q (46.8%), 8p (38.1%), 4q (35.4%), 9p 
(32.3%), 6q (30.8%), 1p (23.5%) and gains of 7q (39.6%), 
7p (30.6%), 20q (25.5%), 12q (24.8%) and 12p (22.8%) [18].
Exploring the molecular alterations, beyond better 
characteristics of pathology and etiology of ccRCC, may 
also have potential clinical implications. VHL inactivation 
may serve an important diagnostic factor, however its 
prognostic relevance in patients with sporadic ccRCCs 
remains undetermined due to low number of studies 
performed and the conflicting results [19–21]. On the 
other hand, most of mutations of chromatin modulating 
genes are associated with advanced stage, metastases, and 
shorter overall survival [12, 22]. Copy number alterations 
in ccRCC tumors have also shown association with clinical 
parameters. Interestingly, deletion of 3p (accompanied by 
other chromosomal aberrations) is correlated with improved 
survival, low tumor stage and grade, and low risk of distant 
metastases [16, 23]. 4p, 9p and 14q deletions and 7q, 8q, 
20q gains are correlated with higher stage, grade, and/or 
worse prognosis [16, 24–27]. Additionally, 1q, 7q, 12q and 
20q gains and deletions of 9p have been associated with 
metastatic risk [27]. Moreover, aCGH profiling of ccRCC 
tumors performed by Moore et al. revealed that regardless 
of stage and grade, more aberrations were observed in 
tumors derived from male patients than from females [18].
Despite of the growing understanding of the 
mechanisms leading to ccRCC, the molecular pathogenesis 
of the disease remains rather poorly understood and 
molecular testing of cytogenetic alterations is not yet 
implemented in a routine diagnostics of ccRCC [28]. To 
widen our knowledge on genetic events involved in tumor 
initiation and progression, we performed whole-genome SNP 
genotyping in 83 ccRCC tumors from Polish population. In 
addition, in proof of concept experiment, we also attempted 
to detect cancer-specific chromosome aberrations in 
circulating cell-free tumor-derived DNA (cfDNA) since this 
non-invasive approach has a great potential in developing 
new molecular or cytogenetic methods for cancer diagnosis 
and prognosis [29, 30]. The analysis of the ccRCC tumors 
was extended with the sequencing of three genes frequently 
mutated in ccRCC: PBRM1, BAP1 and KDM5C in order 
to investigate the extent of the alterations in those genes in 
Polish population of ccRCC patients.
RESULTS
Chromosomal analysis in ccRCC tumors
A total of 83 ccRCC and 12 normal tissues were 
screened by genomic SNP array analysis. An aberrant 
array profile was observed in 73 ccRCCs; 10 tumors 
showed no genomic changes. Five tetraploid or almost 
tetraploid samples showing extremely large number of 
secondary aberrations were excluded from the study as 
the imbalances highly influenced the meta-analysis of our 
study. Further analysis was performed on 78 tissues: 68 
chromosomally abnormal and 10 chromosomally normal 
samples. No acquired genomic copy number variants 
(CNVs) >0.5Mb were detected in the 12 control, randomly 
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Table 1: Frequency of chromosomal aberrations in patients with ccRCC (n=78). Only aberrations present in ≥5% of 
samples are shown
Type of aberration Frequency
3p deletion (including VHL) 82.1% (64)
5q gain (including STC2) 43.6% (34)
5q gain (including CSF1R) 38.5% (30)
Monosomy 14 35.9% (28)
4q deletion (including NEIL) or monosomy 4 26.9% (21)
7q gain (including NAMPT and MCM7) or trisomy 7 26.9% (21)
8p deletion (including DLC1 and NRG1) 26.9% (21)
9p deletion (including CDKN2A) or monosomy 9 25.6% (20)
Chromothripsis (>4 breakpoint on one chromosome arm) 24.4% (19)
6q deletion (including PARK2) or monosomy 6 24.4% (19)
8p deletion (including DLC1, NRG1 and SFRP1) 21.8% (17)
Y chromosome deletion (in 17 out of 45 male patients) 21.8% (17)
5p gain (5p15) 17.9% (14)
5q gain (including VCAN) 15.4% (12)
18q deletion (including DCC) 15.4% (12)
1q gain 12.8% (10)
1p deletion (including RUNX3 and ARID1A) 11.5% (9)
12q gain or trisomy 12 (including CDK4 and NDUFA4L2) 10.3% (9)
13q deletion (including RB1) 10.3% (8)
20q gain (including E2F1 and HCK) or trisomy 20 10.3% (8)
Monosomy 22 10.3% (8)
2q gain (including ZNF804A) 7.7% (6)
8q gain (including COL14A1) 7.7% (6)
10q deletion (including KLLN) 7.7% (6)
17p deletion (including BP53) 7.7% (6)
2q deletion 6.4% (5)
3q gain 6.4% (5)
16q gain (including CDH1) 6.4% (5)
13q gain (including EDNRB) 5.1% (4)
Numbers in parentheses indicate number of patients.
Figure 1: Graphical representation of the most common ccRCC chromosomal imbalances detected by high-resolution 
SNP array analysis. The boxes indicate individual chromosomes with p- and q-arm, respectively. Blue bars signify gains, red bars - 
deletions. Only the somatic chromosomes are depicted on the graph.
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selected, paired kidney tissues samples collected from 
areas histopathological identified as non-tumor tissue.
We identified 28 genomic segments with common 
changes, defined as occurring in ≥5% of the ccRCC tumors 
(Table 1). The general pattern and frequency of somatic 
alterations in the analyzed cohort of tumor samples is shown 
in Figure 1. Significant loss of genetic material was found 
on chromosomes 3p (n=64, 82%), 14q (n=28, 36%), 4/4q 
(n=21, 27%), 8 (n=21, 27%), and 9/9p (n=20, 26%). The 
most significant gain of genetic material was detected on 
chromosome 5q (n=30, 39%) and chromosome 7 (n=21, 
27%). In 24 samples ≥10 CNVs were observed. This group 
is characterized by downregulation of VHL (n=18), as well 
as high tumor stage (T3/4, n=13) and grade (G3/4, n=20) 
suggesting rather advanced disease. In one case we detected 
as many as 39 CNVs, clearly associated with a very severe 
phenotype: the patient presented with high tumor stage, grade 
4, lung metastases, died within 24 months after nephrectomy.
Association of the chromosomal aberrations to 
metastatic stage, TNM stage and survival
Tumor stage assessed by TNM scale is an important 
factor in determining the tumor status. We observed differences 
in the distribution of 28 most common genomic changes 
between high pT stage groups 3 and 4 (larger size of the 
primary tumor) and low pT stage groups (1 and 2), however 
only deletion of the 9p reached the level of significance 
(p=0.038). Univariate logistic regression showed highest 
odds ratio for pT stage 3, 4 (OR 3.5, 95% CI OR 1.2-11.6, 
p=0.03, Table 2) in case of this alteration, suggesting that 
presence of 9p deletion could be used as potential predictor 
of pT parameters. We also grouped ccRCC tumors according 
to the presence of metastases and the regional lymph nodes 
involvement (N) and subsequently analyzed their cytogenetic 
alterations, but no statistically significant correlation between 
the parameters were found in our cohort (data not shown).
Moreover, we investigated association of all 
chromosomal aberrations presented in Table 1 with 
24 months survival. For 75 patients clinical follow up 
was available, six patients were excluded from survival 
analysis: one patient died one month after diagnosis due 
to surgery complications and the follow-up of 5 patients 
was shorter than 2 years. Statistical analysis (Fisher’s 
exact test, n=69) showed significantly shorter survival for 
patients with tumors containing gain of chromosome 20 
(p=0.0286) compared with cases without this aberration. 
This observation was further supported by Kaplan-
Meier survival analysis with log-rank test p=0.011, as 
presented at Figure 2. We next evaluated the independent 
prognostic value of chromosome 20 gain using Cox 
proportional hazards model. Regression analysis showed 
that chromosome 20 gain was significantly associated with 
survival rate, suggesting that its presence can be used as 
a prognostic factor for increased risk of death (HR 4.3; 
95%CI 1.3-13.99; p=0.015), as suggested previously [27].
Chromosomal aberrations involved in the 
transition to higher Fuhrman grade
We analyzed cytogenetic alterations in ccRCC tumors 
according to Fuhrman tumor grade. Tumors at the lowest 
grade, G1, had typically only a few cytogenetic alterations: 
deletion of 3p, 1p, 8p, 10q and gain of 5q, 7, 13q and 16q 
(Figure 3, Supplementary Table 1). The number of large 
aberrations increased with Fuhrman grade: in G2 only 
chromosomes 15, 17, 19 and 21 showed no alterations while 
tumors at the latest grades, G3 and G4, displayed cytogenetic 
changes affecting all chromosomes. Our data support the 
notion that chromosomal changes may be gradually acquired 
during tumor progression from low to high Fuhrman grade. 
At this stage none of these observations reached statistical 
significance in Fisher’s exact test, due to small sample size 
(data not shown, see discussion).
We observed that deletions of 9p (p=0.015) and 
18q (p=0.034) were more common in tumors with high 
Fuhrman grade (3, 4). Value of these chromosomal 
alterations as potential predictors of Fuhrman tumor grade 
(as well as monosomy 14) was confirmed by univariate 
logistic regression which showed highest odds ratio to 
higher grades (G3, G4) in case of these three alterations 
(OR 4.5, 95%CI 1.42-17.74; OR 11.4, 95%CI, 2.01-215.7; 
OR 2.9, 95%CI, 1.06-8.54, respectively; Table 2).
Analysis of ccRCC tumor derived chromosomal 
aberrations in circulating cell free DNA
We investigated if the aberrations present in the 
tumor could be detected in plasma-derived circulating cell 
free DNA (cfDNA). In this proof of concept experiment 
two patients for which SNP array analysis did not detect 
chromosomal aberrations and two patients with maximum 
2 large chromosomal alterations (>75 Mb) were selected for 
cfDNA testing in plasma. cfDNA was isolated from 3ml of 
plasma and the concentration of extracted cfDNA ranged 
from 0.5 - 15.5 ng/µl. Prior sequencing, quality of prepared 
libraries was checked on Agilent Bionalyzer (data not 
shown), with an average library size of 300 bp. During SR-
50 sequencing experiment ~23mln mapped reads per sample 
were obtained on average, with genomic coverage ranging 
from 0.17 to 0.57. A sample with trisomy 21 was used as a 
positive control and was correctly identified as trisomy 21, 
proving the accuracy of the assay (Figure 4). ccRCC specific 
chromosome aberrations were detected, but discrepancies 
between tumor microarray and plasma cfDNA from patients’ 
plasma results were observed as summarized in Table 3. 
Sample 32 showed a normal cfDNA result (Figure 5), which 
was in line with microarray results. Sample 27 showed no 
chromosomal aberrations on microarray analysis of the 
tumor biopsy, however ccRCC specific aberrations could be 
noted on WISECONDOR plot. Very subtle aberrations were 
present in this sample: interstitial 3p deletion, 5q gain and 
low mosaic trisomy 7 and possibly 4q deletion and 8q gain 
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(Figure 6). Sample 69 showed no chromosomal aberrations 
in cfDNA analysis (Figure 7), although microarray on tumor 
biopsy revealed 3p deletion and 5q gain. Strikingly sample 74 
very clearly showed multiple aberrations in cfDNA analysis, 
which are characteristic for ccRCC (Figure 8), such as mosaic 
loss of the entire chromosome 3, whereas microarray analysis 
showed 3p deletion only.
Chromosomal aberrations in PBRM1, BAP1 and 
KDM5C loci
The first comprehensive analysis of genes mutated 
in ccRCC was performed in the The Cancer Genome Atlas 
project [4]. Newly identified genes, involved in chromatin 
remodeling, were represented by PBRM1, BAP1, SETD2, 
KDM5C and KMD6A. Here, in order to specifically 
identify chromosomal rearrangements spanning PBRM1, 
BAP1 and KDM5C in the cohort of Polish ccRCC patients, 
we performed fine mapping of these loci with a cut-off 
0.5 MB. PBRM1 and BAP1 are located at the short arm 
of chromosome 3 (3p21.1 and 3p21, respectively), in a 
vicinity of VHL; KDM5C is located on chromosome X 
(Xp11.22-p11.21). In the majority of the investigated 
cases all 3 genes are deleted (n=60). Only in one sample 
showing VHL and PBMR1 deletion we observed normal 
copy number of BAP1. In one sample we detected normal 
copy number of VHL with BAP1, PBRM1 deletion, 
however the region 3p25 showed LOH (data not shown). 
We believe that the analysis of LOH is very relevant in 
case of individual samples, where chromosome analysis 
did not show 3p deletion. However, during the analysis on 
the cohort-level no enrichment in 3p LOH was observed 
and only one sample mentioned above displayed 3p LOH. 
KDM5C mosaic gain was observed in 2 samples: one 
showing trisomy X and the second showing structural 
X chromosome rearrangement. KDM5C mosaic deletion 
was detected in 3 samples, all with mosaic chromosome 
X monosomy. None of these patients were tested for 
constitutional karyotyping, and in consequence we cannot 
exclude the germline origin of these aberrations.
Identification of mutations in PBRM1, BAP1 and 
KDM5C in Polish ccRCC patients
To further characterize our patient’s cohort and 
identify frequently occurring mutations in ccRCC tumors 
we performed targeted amplicon sequencing of the entire 
coding regions and adjacent intronic sequences of the 
PBRM1, BAP1 and KDM5C genes. 28 amplicons with 
length between 1599 – 5341 nucleotides were generated. 
The sequencing run yielded a total of 3.86 Gbases of data, 
with 85% of bases having a Phred quality score (Q score) 
≥Q30, with cluster density of 898 ± 27 K/mm2, with 75.21 
± 6.45% of the clusters passing QC filters. Average total 
number of reads was 56 727 (ranging from1751 to 90216) 
out of which 88.4% was aligned to target regions. The 
observed read depth in 82 samples was >20 per base with 
Q≥30 (average coverage 72.9, range 22.2-122.5). Samples 
with coverage below 20x were excluded from the analysis.
Variant calling performed with StrandNGS resulted 
in the identification of 12 common and 94 rare variants, 
present in ≤10% of patients (Supplementary Table 2 
and 3, respectively). Common variants were found only 
in KDM5C (n=7) and PBRM1 (n=5) genes. All except 
for one were located in intronic sequences, 3 were 
known, 6 were novel and 3 have been reported as single 
nucleotide substitutions by dbSNP, but in our sample set 
we observed small deletions and insertion at the reported 
positions (for details see Supplementary Table 2). 
Table 2: Univariate logistic regression analysis of association between high pT (3, 4), high Fuhrman grade (3, 4) and 
chromosomal changes in ccRCC tumors
CNV OR 95% CI P-value
pT 9p Del 3.5 1.2-11.6 0.03
Fuhrman grade Monosomy 14 2.9 1.06-8.54 0.04
18q Del 11.4 2.01-215.7 0.02
9p Del 4.5 1.42-17.74 0.01
Figure 2: Overall survival analysis of sporadic 
ccRCC patients (n=64, 24 month follow-up), based on 
chromosome 20 copy number alteration. Study included 
6 patients with chr20 gain and 58 patients with normal CN.
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As shown in Figure 9A the majority of rare variants 
were present in PBRM1 (69%, n=69), the remaining 
variants were present at nearly equal frequencies in 
KDM5C (16%, n=16) and BAP1 (15%, n=15). 70% of 
all identified somatic variants were intronic and 85% 
represent substitution type (Figure 9B and 9C). In 10 
Figure 3: Chromosomal imbalances associated with grading of ccRCC tumors. The analysis was performed on 77 tumors: 
grade 1 (n=6), grade 2 (n=26), grade 3 (n=29), grade 4 (n=16). Arrows indicate successive acquisition of chromosomal abnormalities (gains 
– blue, deletions - red) with increasing Fuhrman grade, depicted on the left side of the graph.
Figure 4: Chromosomal aberrations in cfDNA detected by shallow sequencing using WISECONDOR software. 
Aberration calling results from the sliding window method and the individual bin method. Positive control shows trisomy 21 in cfDNA.
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patients (12%) we found >3 variants in PBRM1, with 
prevalence of intronic mutations. 38% of all identified 
variants (n=42) were not previously reported, 62% were 
reported in dbSNP (Figure 9D). In further analysis we 
focused on variants present in UTR’s, coding sequence 
and splice sites that can have potential functional impact 
on encoded protein, and discarded all synonymous 
and intronic alterations. To determine the functional 
significance of identified single nucleotide and complex 
variants we utilized Variant Effect Predictor (Ensembl) 
and MutationAssessor r3. 23 variants were taken 
into account, out of which four were predicted to be 
deleterious and possibly/probably damaging, all present 
in single samples (Table 4). One novel KDM5C variant 
is located outside of the peptidaseC12 functional 
domain leading to an amino acid change D376H 
(Figure 10). The remaining three variants were found 
in PBRM1 gene (Figure 10), of which two are novel 
(p.S743P, p.K1016N). Variant p.S605F was previously 
described in melanoma and kidney tumor samples 
(COSMIC database) [31–33]. All possibly/probably 
damaging PBRM1 variants were present in functional 
domains: bromodomain 5, bromo-adjacent homology 
domain 1 and bromodomain 4, respectively. Due to 
very limited number of individuals with the mutations 
we were not able to correlate their presence with the 
clinical parameters, nor to test their prognostic and 
diagnostic utility.
Table 3: Comparison of SNP array analysis of tumor samples and cfDNA derived from plasma of ccRCC patients
Sample 
number
T N M F SNP array 
analysis
cfDNA 
sequencing*
cfDNA 
mapped 
reads
Conclusions
32 pT1a 0 no G2 normal results normal results 26.8 mln cfDNA results are fully in line 
with microarray analysis of tumor 
sample.
27 pT3a 0 no G4 normal results very low 
mosaic 
aberrations: 3p 
deletion, 4q 
deletion, 5q 
gain, chr7 gain, 
8q gain
15.8 mln cfDNA probably more representative 
than a single biopsy, normal array 
results are likely due to tumor 
heterogeneity. In this case cfDNA 
could have potentially prognostic 
value.
69 pT1a 0 yes G3 abnormal 
results: 3p 
deletion, 3q 
deletion, 5q 
gain
normal results 40.8 mln Discrepant result can be explained 
possibly by low primary tumor 
cfDNA fraction, which can cause 
false negative results. This patient 
should be resampled, however it was 
not possible in our research settings.
74 pT4 NA no NA abnormal 
results: 3p 
deletion
evident 
complex 
chromosome 
aberrations: 
1p deletion, 
chr3 deletion, 
7p gain, 8p 
deletion, 8q 
gain, chr11 
gain, chr12 
deletion, chr13 
deletion, chr14 
gain, 16q gain, 
chr20 gain, 
chr22 gain
19.1 mln cfDNA showed multiple 
aberrations typical for ccRCC, 
whereas the biopsy showed only 
3p deletion. cfDNA is probably 
more representative than a single 
biopsy, due to heterogeneity of the 
tumor. In this case cfDNA could 
have potentially prognostic value as 
chr20 gain was visualized by cfDNA 
and not by microarray on a single 
biopsy.
*Aberrations smaller than 20Mb and concerning chromosome 19 are not listed due to the limitations of the method.
Abbreviations: T, tumor size; N, lymph node involvement; M, metastasis; F, Fuhrman grade; NA, data not available.
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Figure 5: Chromosomal aberrations in cfDNA. Negative control (sample 32) shows no chromosomal aberrations.
Figure 6: Chromosomal aberrations in cfDNA. Sample 27, selected as negative control, shows very low mosaic chromosome 
aberrations: 3p deletion (red line), 5q gain (blue line) as well as mosaic trisomy 7 and possibly 8q gain and 4q deletion.
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Figure 7: Chromosomal aberrations in cfDNA. No chromosomal aberrations were detected in sample 69.
Figure 8: Chromosomal aberrations in cfDNA. Sample 74 shows clear multiple chromosome aberrations characteristic for ccRCC: 
a.o. deletion of chromosome 1, deletion of chromosome 3, 7p gain, 8p-, 8q gain, trisomy 11, deletion of chromosome 13, trisomy 14, 16q 
gain, trisomy 20 and trisomy 22.
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DISCUSSION
Chromosomal aberrations in ccRCC tumor 
biopsies
SNP microarray analysis was performed to 
characterize the chromosome aberrations in the cohort 
of Polish patients with ccRCC. Genome-wide analyses 
indicated that deletions at chromosomal arms 3p, as well 
as gains of 5q and 7, are indispensable for the development 
of ccRCC [18, 26, 34–37] and our data showed that these 
were the most common chromosome aberrations in our 
cohort as well. Moreover, deletions at 1p, 4p, 4q, 8p, 9p, 
9q, 13q, 14q, and 18q have been found to correlate with 
higher malignancy grades and tumor stages in ccRCC 
[15, 18, 25, 26, 36, 38–42]. Our data are in line with these 
findings, showing a correlation between deletions at 9p and 
with higher pT. Unfortunately we did not find a correlation 
between chromosomal rearrangements in metastatic tumors 
and patient survival, most probably due to relatively short 
24 month patient follow-up. We did however detect a 
statistically significant correlation between deletion of 
chromosome 20 and the survival time, which was noted 
before as well, but not as a common finding [27].
As the majority of ccRCC tumors are diagnosed 
in the advanced metastatic stage resulting in dramatic 
decrease of patient survival, the number of grade 1 tumors 
is very low in all publically available published data and 
very often samples with grade 1 and 2 were analyzed as 
one group. We were especially interested to investigate 
early grade samples to search for the primary chromosome 
aberrations and to identify the ones likely involved in 
tumor progression. Only 3p and 8p deletion as well as 
5q, 7, 13q and 16 gains were seen in the Fuhrman grade 
1. To support our findings we analyzed additionally 10 
freely accessible samples with grade 1 from ccRCC tumor 
samples in NEXUS DB (http://www.biodiscovery.com/
genomic-databases-nexus-db) (the cohort of publically 
available data from The Cancer Genome Atlas (TCGA) 
(http://cancergenome.nih.gov). All samples with grade 
1 except one confirmed our results presented in Figure 
3. This additional analysis may support the fact that 
the Fuhrman grade assessed microscopically is less 
accurate that genome wide SNP analysis. The recognition 
of primary aberrations and prognostic secondary 
chromosome aberrations is crucial if non-invasive genetic 
testing for the diagnosis and follow up of ccRCC tumor 
would become clinically available.
Figure 9: Statistics of somatic variant calling in tumors derived from Polish ccRCC patients.
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Chromosomal aberrations in cell free DNA
Analysis of circulating cfDNA (liquid biopsies) is a 
promising alternative for classical invasive tissue biopsies 
and has a great potential in developing new molecular or 
cytogenetic methods for cancer diagnosis and prognosis 
[29, 30]. Advances in technology, including allele-specific 
PCR, digital PCR, MethyLight PCR, next generation 
sequencing (NGS) and microarrays, allow analyses of 
circulating cfDNA [43]. However, the accurate detection 
of copy number alterations is still challenging since only a 
very small fraction of total cfDNA is derived from tumors 
in most patients. The presence of tumor cell-free DNA in 
plasma of patients with ccRCC has been shown before 
[44, 45], therefore we attempted to detect the chromosome 
aberrations characteristic for ccRCC in patients’ plasma 
using shallow NGS and WISECONDOR software [46]. In 
our proof of concept experiment we show cfDNA contains 
more advanced chromosome aberrations than detected by 
the genomic SNP array on tumor sample. Heterogeneity 
of tumor samples has been described before [47] and it 
is accepted that a single tumor biopsy sample may not 
be fully representative for the whole tumor, especially 
if the tumor size is very large. We also visually detected 
a number of CNVs in cfDNA that were not “called” by 
the software, likely due to low concentration of cfDNA 
present in the plasma of the patient or too low coverage. 
Therefore, in future if cfDNA is going to be implemented 
in a diagnostic setting, the assessment of the tumor cfDNA 
fraction and determination of reliable sample sequencing 
coverage may be crucial to avoid false negative results. 
Also a carefully controlled and standardized sample 
collection and preparation is a precondition for reliable 
results [48].
Unfortunately our preliminary cfDNA data did not 
allow us to correlate our results to clinical outcome. More 
tests are necessary to assess whether the cfDNA analysis 
reflects the clinical prognosis in more accurate manner than 
analysis of a single tumor tissue biopsy and whether the 
tumor heterogeneity could be overcome by cfDNA testing.
Mutation analysis in PBRM1, BAP1 and KDM5C
Data obtained from The Cancer Genome Atlas 
Research Network revealed essential role of chromatin 
remodeling genes (e.g. PBRM1, BAP1 and KDM5C) in 
ccRCC tumorigenesis. However, their contribution to 
cancer development and the functional consequences of 
the mutations still require further studies. Here, we aimed 
to test the frequency of previously reported and to identify 
Figure 10: Schematic representation of relative positions of potential mutations within KDM5C, BAP1 and PBRM1 
transcripts. Symbols indicate: green circles, missense mutation; red circles, nonsense mutation. BD1-6: bromodomain 1-6; BAH1 
and BAH2: bromo-adjacent homology domains 1 and 2; HMG: high mobility group domain; UCH: Peptidase C12: belongs to ubiquitin 
C-terminal hydrolase family; JmjN and JmjC belong to jumonji family of transcription factors; ARID: AT-rich interaction domain; PH, ZF: 
zinc finger domains; PLU1: PLU-1-like protein. Figures were generated with cBio MutationMapper [60, 61].
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novel mutations in these 3 genes. In Polish ccRCC patients 
SNVs frequency (within coding region and splice sites) 
in our cohort display similar range as mutation frequency 
reported previously for BAP1 (6-17%) and KDM5C (4–
9%) [49–51]. In case of PBRM1 we observed markedly 
lower level of variants in Polish population (11%) 
than reviewed by Piva and colleagues (26-52%) [51]. 
However, it should be noted that mutations spectra for 
all above mentioned genes varies greatly between studies 
i.a. due to different patient groups, sequencing methods 
and bioinformatic approaches. Moreover, it may be a 
characteristic feature for our cohort or result from quite 
stringent filtering of called variants.
We did not observe a significant co-occurrence 
of detected variants and VHL mutations (identified 
with standard Sanger sequencing, data not shown), as 
demonstrated on Figure 11. Also in contrast to previous 
reports, variants present in BAP1 and PBRM1 were not 
mutually exclusive in our sample set [13, 33, 50, 51]. 
BAP1 loss was reported to correlate with high Fuhrman 
nuclear grade, higher tumor stage, and worst overall 
survival [13, 33]. We noted a similar tendency only in 
case of tumor grade (Supplementary Table 4), but due to 
the smaller sample size no clear-cut conclusions could be 
made.
Three novel non-synonymous coding variants and 
one previously reported were predicted to be damaging 
and/or deleterious—one in KDM5C and three in 
PBRM1, suggesting possible correlation with the ccRCC 
phenotype. PBRM1 is a member of the SWI/SNF 
complex involved in chromatin remodeling and contains 
6 tandem bromodomains binding lysine residues modified 
by acetylation [52]. S605F and S743P substitutions are 
present in bromodomain 4 and 5, respectively, suggesting 
that they may impair chromatin targeting of PBRM1. 
Although not present in dbSNP database, p.S605F has 
been reported in COSMIC in ccRCC patients as well 
as alterations within residue 743: p.E742_I745del and 
p.S743F. In addition to bromodomains, two bromo-
adjacent homology (BAH) domains, possibly implicated 
in protein-protein-interactions are present in PBRM1 
[53]. These domains are frequent targets of missense 
mutations in renal cancer, which suggest that K1016N 
substitution present in BAH1, although not reported 
before, may have functional impact on the protein 
function. In contrast, D443H is located outside of 
KDM5C functional domains, however close to the PHD 
finger thus we can speculate that this variant could 
influence rather DNA binding than direct chromatin 
remodeling functions of this lysine-specific demethylase. 
Data analysis with Variant Effect Predictor pointed to 
few more variants as having potentially high functional 
impact. These include four novel variants leading to 
frameshift and one introducing premature stop codon 
within bromodomain 4 at position 602 of PBRM1. E602* 
is not reported in dbSNP/ClinVar but present in COSMIC 
database and has been found in one Polish patient with 
ccRCC. The catalytic peptidase C12 domain of BAP1 
which has a deubiquitinase activity is often targeted 
by missense mutations in ccRCC [33]. One variant 
found in our patients is novel and leads to a frameshift 
(Figure 10). Loss of STOP codon (*730C) is also novel, 
but amino acid changes to G or R have been reported 
previously (COSMIC database) suggesting functional 
importance of this amino acid change. In conclusion, 
bioinformatics predictions indicated that 9 out of 19 
potentially damaging variants reported in current study 
may have a functional impact on the proteins and be 
linked to the ccRCC development. However, it is difficult 
to predict the consequences of the SNVs in terms of 
protein function impairment using only computational 
methods, hence further functional analysis are required 
to establish their significance. It should be also 
emphasized that in contrast to VHL, in case of PBRM1, 
BAP1 and KDM5C no gene silencing due to promoter 
hypermethylation has been reported suggesting that gene 
function impairment is rather entirely achieved through 
mutations within coding regions and regulatory elements 
[54]. Therefore, functional studies on in BAP1, KDM5C, 
PBRM1 mutations impact on gene/protein function are 
required. There is also necessity of population specific 
analysis of ccRCC mutations (germline and somatic) and 
their functional consequences, which is supported by our 
finding that as much as 38% of all identified variants 
Figure 11: Distribution of variants in affected samples in relation to VHL mutations. Upper panel shows variant distribution 
in PBRM1, KDM5C and BAP1 genes in 80 ccRCC cases. Matrix represents individual variants in patients samples, color or symbol-coded 
by type of genetic alteration. Note that intronic variants, often occurring more than once in a single sample, are indicated on the figure as 
single event. Lower panel shows mutations found in VHL gene by Sanger sequencing. All samples with gene alteration are indicated in red, 
x, data not available.
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in BAP1, KDMC5, and PBRM1 were not previously 
reported in dbSNP database. This study aimed solely 
to identify the mutations in the three abovementioned 
genes in our sample set. Their clinical relevance, in 
combination with prognostic and diagnostic utility, 
remain unclear and require additional studies.
CONCLUSIONS
Our data suggest that whole genome SNP micro-
array allows identification of prognostic chromosome 
aberrations and it may be used in clinical settings 
especially in borderline case for more accurate Fuhrman 
grade assessment. However tumor heterogeneity must 
be taken into account. Chromosome analysis of cfDNA 
may allow more accurate diagnosis of tumor aberrations 
and therefore the correlation between the chromosome 
aberrations in cfDNA and clinical outcome should be 
studied in larger cohorts. The functional studies on 
possibly pathogenic variant in BAP1, KDM5C, and 
PBRM1 as well as study of both somatic and germline 
variations in larger sample sets would be necessary for 
better risk assessment.
MATERIALS AND METHODS
Sample collection
All kidney tissue specimens were collected between 
December 2009 and November 2013 from patients 
undergoing radical or partial nephrectomy for ccRCC 
(in collaboration with the Department of Urology and 
Urological Oncology, Poznan University of Medical 
Sciences). The study was approved by Local Bioethical 
Committee at Poznan University of Medical Sciences 
(no. 1124/12) and all participants gave written informed 
consent. Samples were stored at −80°C.
The samples used in this study originated from 
83 histopathologically confirmed sporadic ccRCC 
tumors from patients ranging from 30-87y of age, with 
a median of 71y, at diagnosis while mean follow-up time 
was 33 months. Disease progression was characterized 
as local neoplasm recurrence or distant metastasis. 
Pathological and clinical data are presented in Table 4 
and Supplementary Table 5. Control kidney tissue was 
collected from areas histopathologically identified as non-
tumor tissue, from 12 randomly selected patients.
Expression studies
Real-time PCR-based analysis of VHL, HIF1A 
and EPAS1 genes expression was performed using 
SYBR® Green master mix (LifeTechnologies) and 
the Eco Real-Time PCR System (Illumina Inc., San 
Diego, CA).
SNP array assay
83 tumor samples and 12 non-tumor controls 
were analyzed using HumanOmniExpress12v1.1 SNP 
array (733K BeadChip of Illumina Inc., San Diego, 
CA). Genomic DNA was isolated from homogenized 
tissue using Gene MATRIX Universal DNA Purification 
Kit (EurX, Gdańsk, Poland) following manufacturer’s 
protocol. 200 ng of DNA was used as an input for a single 
array. DNA amplification, tagging and hybridization were 
performed according to the manufacturer’s protocol. The 
array slides were scanned on a HiScan SQ (Illumina Inc., 
San Diego, CA).
Data analysis was performed using GenomeStudio 
version 2011.1 and Nexus Copy Number 7.0-7.5 
(BioDiscovery, El Segundo, CA, USA) with SNP-FASST2 
Segmentation. The HapMap control set provided by the 
manufacturer was used as a control. Standard settings 
for SNP arrays in Nexus were adjusted: homozygous 
frequency threshold of 0.95 and minimum loss of 
heterozygosity (region with LOH) length of 2000 kb and 
>50 probes were set. QC measurement in Nexus was used 
as a measure for the array profile quality. Samples with 
QC < 0.13 were further analyzed. All samples met quality 
Table 4: Clinical characteristics of the ccRCC patients, 
n = 83
Clinical parameter Number of 
patients
  Age (years) 30-87 (median 63.2)
  Males/Females 45 (54.2%)/38 (45.8%)
Clinical outcome
  Alive (≥24months after 
nephrectomy) 62 (79.5%)
  Deceased 16 (20.5%)
Follow-up time (months) 1-55
pT
  1 39 (47.5%)
  2 4 (4.9%)
  3 35 (42.7%)
  4 4 (4.9%)
Fuhrman grade
  1 6 (7.4%)
  2 27 (33.3%)
  3 30 (37%)
  4 18 (22.2%)
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criteria for further analysis. The resolution of 500 kb was 
generally applied. UCSC built Hg19 (Human Mar. 2009 
(NCBI37/hg19) Assembly) was used to analyze the data. 
The SNP array data of our project is deposited in Nexus 
DB Biodiscovery (http://www.biodiscovery.com/genomic-
databases-nexus-db) under project name: ccRCC_Kluzek_
[publication date].
Analysis of chromosomal aberrations in 
circulating cell free DNA (cfDNA)
Circulating cell free DNA (cfDNA) from serum 
samples of 4 patients with ccRCC, 7 patients without 
chromosomal aberrations (reference set) and a control 
sample (trisomy 21) was extracted with QIAamp® 
Circulating Nucleic Acid Kit (QIAGEN) according to 
the manufacturer’s instructions. Concentration of cfDNA 
was measured on Qubit® fluorometer using the dsDNA 
HS Assay Kit (Life Technologies, Carlsbad, CA, USA). 
Libraries were constructed using TruSeq® DNA Library 
Sample Preparation Kit (Illumina Inc., San Diego, CA) 
and/or NEBNext® Ultra™ DNA Library Prep Kit for 
Illumina (New England BioLabs Inc.). Libraries were 
quantified on Qubit and the quality was assessed using a 
bioanalyzer on a DNA 1000 Chip (Agilent Technologies). 
The libraries in 15 pmol concentration were sequenced on 
the HiScanSQ platform (Illumina, Inc., San Diego, CA), 
with Reagent Kits v2, 1×50 bp reads. The sequenced reads 
were mapped to the reference genome NCBI37/hg19 using 
BWA with zero mismatches allowed, duplicates were 
removed with SAMtools and resulting BAM files were 
analyzed with WISECONDOR [46].
PBRM1, BAP1 and KDM5C amplicon 
sequencing in tumor samples
28 individual primer pairs (Supplementary 
Table 6) designed in PrimerBlast or OptimusPrimer 
(Pharmacogenomics Centre; http://op.pgx.ca) software 
were used to amplify the complete coding sequences 
and adjacent exon–intron boundaries of the PBRM1, 
BAP1 and KDM5C genes (Supplementary Figure 1) in 95 
samples (83 tumors and 12 controls). PCR amplification 
was performed using KAPA HiFi polymerase (Kapa 
Biosystems) in a 20µL reaction mix with 50ng of 
genomic DNA. All amplicons ranging from 1599 to 5341 
bp in length were amplified using DNA Engine Dyad® 
Peltier Thermal Cycle (BioRad). All PCR products were 
examined by electrophoresis in ethidium bromide stained 
0.7% agarose gel.
2nM of amplicons from each of the 28 PCR 
reactions were pooled and purified with AmpureXP beads 
(Beckman Coulter, Krefeld). DNA concentration of pooled 
samples was determined using the HS dsDNA Assay Kit 
(Invitrogen, Paisley, UK) and measured with a Qubit 2.0 
Fluorometer (Invitrogen). NexteraXT DNA Sample Prep 
Kit (Illumina Inc., San Diego, CA) was used for library 
preparation, following standard protocol. Libraries were 
pooled at equimolar concentration and sequenced on an 
Illumina MiSeq (PE, v2, 2x75 reads) with a 15% PhiX 
spike-in.
FASTQ files were subjected to error correction using 
Blue with default parameters [55]. K-mer length was set to 
25. Flexbar was used to remove adapters, low quality reads 
(Phred <30), over-represented sequences, trim read ends (15 
bases at the 5’ end, 10 bases trimmed at the 3’ end), and to 
remove short sequences (less than 105 bp) [56]. Mapping 
of purified reads to the human reference genome (NCBI37/
hg19 Assembly) was performed for each sample separately 
using Soap3-dp aligner with default parameters [57].
StrandNGS (Strand Life Sciences) software was used 
for variant calling, with default analysis settings and dbSNP 
human Build 146, COSMIC and ClinVar databases were 
used for identification of known variants. Calls were then 
filtered based on a score specified in StrandNGS (range 
0-1000). Variants with score ≥800 were used for subsequent 
analyses, after confirmation by direct visual inspection of 
amplicon reads in Integrative Genomics Viewer. Due to 
difficulties in accurate mapping of short reads containing 
complex variations, especially insertions and deletions 
(indels), DNA variants encompassing >3bp were validated 
using Sanger sequencing [58]. Non-synonymous variants 
within coding sequence were further analyzed for the 
likelihood of functional impact. Predictions were performed 
with two different tools: MutationAssessor (http://
mutationassessor.org/r3/) and Variant Effect Predictor 
(VEP) from Ensembl database (http://www.ensembl.org).
Statistical analysis
Association of the chromosomal aberrations with 
metastasis, disease stage, tumor size or survival was 
analyzed using Fisher’s exact test, Kaplan–Meier survival 
analysis and the log rank test (GraphPad Prism Software 
5.0, San Diego, CA). Statistical tests were two sided with 
default significance level of 0.05. Univariate logistic 
regression and univariate Cox regression were performed 
using R statistical software v3.2.0 as described previously 
[59].
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